Clinical Trial Update: A Study of Amivantamab in People With Esophagogastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for amivantamab in esophagogastric cancer; the study is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophagogastric Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING